

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H.

Lancet HIV

2019; 6(6):e355-e363

ARTICLE IDENTIFIERS

DOI: 10.1016/S2352-3018(19)30077-3

PMID: 31068270

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: 2015243187

pISSN: 2405-4704

eISSN: 2352-3018

OCLC ID: 904051032

CONS ID: not available

US National Library of Medicine ID: 101645355

This article was identified from a query of the SafetyLit database.